Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hansa Biopharma AB ( (SE:HNSA) ) has provided an update.
Hansa Biopharma will publish its year-end report for January–December 2025 on 11 February 2026 and hold a conference call the same day, during which senior management will review financial results and provide an update on the company’s business and development pipeline. The webcasted presentation, supported by slides available on the company’s website, underscores Hansa’s efforts to maintain transparency with investors and other stakeholders as it advances its IgG-cleaving enzyme platform and late-stage assets in rare immunological diseases.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK37.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative, life-altering treatments for patients with rare immunological conditions. Built around its proprietary IgG-cleaving enzyme technology platform, the company targets serious unmet medical needs in transplantation, gene therapy and autoimmune diseases, with a portfolio that includes imlifidase, a first-in-class IgG antibody-cleaving enzyme enabling kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule in development for Guillain-Barré syndrome. Headquartered in Lund, Sweden, Hansa Biopharma operates in Europe and the U.S. and is listed on Nasdaq Stockholm under the ticker HNSA.
Average Trading Volume: 649,788
Technical Sentiment Signal: Buy
Current Market Cap: SEK3.83B
See more insights into HNSA stock on TipRanks’ Stock Analysis page.